EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Hypermethylation of HIST1H4F in Tao Brush Samples as a Complementary Biomarker for Triaging Patients at Risk of Endometrial Carcinoma

Qi Lu, Xiaoling Duan, Yanchun Huang, Chen Xia, Jiangjing Yuan, Qinmei Li, Yunuan Wang

OncoTargets and Therapy · 2026-11 · Volume 19 · 1-12

DOI: 10.2147/ott.s639678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift OncoTargets and Therapy, 2026-11. Verfasst von Qi Lu und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Endometrial carcinoma (EC) is a prevalent gynecological malignancy with a favorable prognosis when diagnosed at an early stage; however, effective minimally invasive triage tools for symptomatic or clinically selected patients with suspected endometrial lesions remain lacking. This study aimed to evaluate the methylation level of HIST1H4F in endometrial brush samples as a potential complementary biomarker for triaging patients at risk of EC who may benefit from confirmatory hysteroscopy. Patients and Methods: We analyzed methylation profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to identify HIST1H4F as a candidate biomarker. Quantitative methylation-specific PCR (qMSP) was employed to detect HIST1H4F methylation in 121 endometrial tissue samples and 118 Tao brush samples. Diagnostic performance was evaluated using sensitivity, specificity, and area under the receiver operating characteristic curve (AUC).

Results

HIST1H4F methylation levels were significantly higher in EC tissues than in normal controls, with AUC values of 0.993 (TCGA) and 0.975 (GEO). Clinical validation confirmed significantly elevated HIST1H4F methylation in EC and precancerous lesions versus normal tissues (p < 0.001). In Tao brush samples, the sensitivity and specificity for EC detection were 84.00% and 88.64%, respectively (AUC = 0.907). For stage I EC, the AUC reached 0.922, suggesting potential diagnostic value for early-stage disease.

Conclusion

HIST1H4F hypermethylation is a promising complementary triage biomarker for EC and its precancerous lesions in symptomatic or clinically selected patients. When combined with Tao brush sampling, this biomarker offers a novel, minimally invasive triage strategy for identifying patients at risk of EC who may benefit from confirmatory hysteroscopy. However, as an exploratory validation study, further validation in larger, prospective cohorts is warranted. Keywords: endometrial carcinoma, methylation, HIST1H4F , Tao brush, early detection

Zitieren

APA

Lu, Q., Duan, X., Huang, Y., Xia, C., Yuan, J., Li, Q., & Wang, Y. (2026). Hypermethylation of HIST1H4F in Tao Brush Samples as a Complementary Biomarker for Triaging Patients at Risk of Endometrial Carcinoma. OncoTargets and Therapy, Volume 19, 1-12. https://doi.org/10.2147/ott.s639678

Vancouver

Lu Q, Duan X, Huang Y, Xia C, Yuan J, Li Q, et al. Hypermethylation of HIST1H4F in Tao Brush Samples as a Complementary Biomarker for Triaging Patients at Risk of Endometrial Carcinoma. OncoTargets and Therapy. 2026;Volume 19:1-12. doi:10.2147/ott.s639678

BibTeX
@article{Lu2026,
  author = {Lu, Qi and Duan, Xiaoling and Huang, Yanchun and Xia, Chen and Yuan, Jiangjing and Li, Qinmei and Wang, Yunuan},
  title = {Hypermethylation of HIST1H4F in Tao Brush Samples as a Complementary Biomarker for Triaging Patients at Risk of Endometrial Carcinoma},
  journal = {OncoTargets and Therapy},
  year = {2026},
  volume = {Volume 19},
  pages = {1--12},
  doi = {10.2147/ott.s639678}
}
Kostenlos starten →